.jpg)
Transcend rises above threshold for success, linking MDMA analog to PTSD improvements in phase 2
Transcend Therapeutics has glided over the bar for success, linking its MDMA analog to improvements in PTSD symptoms that began on Day 8 and persisted through Day 64 of its phase 2 trial.
Transcend Therapeutics has glided over the bar for success, linking its MDMA analog to improvements in PTSD symptoms that began on Day 8 and persisted through Day 64 of its phase 2 trial.
